An interventional study of End-expiratory lung volume measurement and incremental PEEP titration in Acute Respiratory Distress Syndrome, sponsored by Centre Hospitalier Intercommunal Aix-Pertuis. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-20.
Sponsored by Centre Hospitalier Intercommunal Aix-Pertuis · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Respiratory Distress Syndrome with a site in France — 41 open to participants now, 43 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 63rd largest by planned enrollment of the 118 interventional ones that give a count, is one of 61 that started in 2020, is one of 77 with no phase, and was the 100th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →41 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Centre Hospitalier de la côte Basque · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 26 · Phase 4 5
First in 2002; this study’s year is marked. 61 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 50 across the 118 interventional studies, 80 across the 97 observational. Of the 145 that completed or were terminated, 4 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 217 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Intercommunal Aix-Pertuis is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Centre Hospitalier Intercommunal Aix-Pertuis has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
12 of the studies in Respiratory Distress Syndrome with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368092Phase 3University Hospital, Strasbourg, FranceInhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma | 2027-09-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06254313University Hospital, BordeauxThe Role of Cxcr4Hi neutrOPhils in InflueNza | 2026-12 |
| NCT06119516Assistance Publique - Hôpitaux de ParisTranspulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. | 2027-04-04 |
| NCT06807983University Hospital, ToulouseLUng and Cardiac Ultrasound for REspiratory Distress in ElDerly | 2027-05-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mechanical ventilation of the patient with acute respiratory distress syndrome is one of the first therapies.
The application of positive end expiratory pressure is recommended but the question remains "How to set the best positive end-expiratory pressure (PEEP) level for each patient? ". Different titration techniques have been studied on oxygenation and respiratory mechanics parameters without reaching a consensus. Currently we have a module that is connected to the ventilator to collect the patient's lung volume. It will therefore allow us to optimize the settings of the ventilator and to set the best level of positive end-expiratory pressure "best peep" in order to individualize our treatment for each patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* end-expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o * incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o
Procedure: End-expiratory lung volume measurement and incremental PEEP titration
* End expiratory lung volume measurement procedure according to the PEEP level set by the clinician, respecting a Vt at 6ml/kg IBW and Pplat\<28cmH2o * incremental PEEP titration procedure in 5 steps starting from 5cmH2o up to 20cmH2o
Observe end-expiratory lung volume change during an increasing PEEP titration procedure in patients with moderate to severe ARDS
Time frame: 1 day
Define a threshold of end-expiratory lung volume variation to help determine optimal PEEP
Time frame: 1 day
Analyzing the effect of PEEP titration on static compliance and dynamic strain
Time frame: 1 day
Effect of PEEP titration on hematosis via the calculation of the Pao2/Fio2 ratio for each PEEP step thanks to the measurement of Pao2 on arterial gasometry
Time frame: 1 day
Study the correlation between % change in end-expiratory lung volume and improvement in hematosis (Pao2/Fio2)
Time frame: 1 day
Compare end-expiratory lung volume variations according to the type of ARDS (severity, focal or diffuse, pulmonary or extra-pulmonary etiology)
Time frame: 1 day
Evaluate the hemodynamic tolerance of this procedure with the mean arterial pressure obtained by invasive blood pressure, noradrenaline dosage variation per procedure, lactate (obtained by arterial blood gas)
Time frame: 1 day
Plan to share: No
Started Jan 2020 (actual). Primary completion is estimated for Nov 2020, 10 months after the start.
Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 10 months is below that.
Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Centre Hospitalier Intercommunal Aix-Pertuis